{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:12:04Z","timestamp":1759399924500,"version":"build-2065373602"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,2]]},"DOI":"10.7759\/cureus.93695","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:53:11Z","timestamp":1759398791000},"source":"Crossref","is-referenced-by-count":0,"title":["Prescribing Patterns of Evolocumab and Alirocumab in Patients With Familial Hypercholesterolemia: A Cross-Sectional Study Using the National Ambulatory Medical Care Survey, 2018\u20132019"],"prefix":"10.7759","author":[{"given":"Efeturi M","family":"Okorigba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehinde H","family":"Jinadu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nneka","family":"Muoghalu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Adu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruthel S","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinyemi","family":"Akinwumiju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2408236","article-title":"Familial hypercholesterolemia: pitfalls and challenges in diagnosis and treatment","volume":"24","author":"Arnold N","year":"2023","unstructured":"Arnold N, Koenig W. Familial hypercholesterolemia: pitfalls and challenges in diagnosis and treatment. Rev Cardiovasc Med. 2023, 24:236. 10.31083\/j.rcm2408236","journal-title":"Rev Cardiovasc Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen LE","year":"2017","unstructured":"Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, Tu JV. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017, 7:e016461. 10.1136\/bmjopen-2017-016461","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1316","article-title":"It is time to screen for homozygous familial hypercholesterolemia in the United States","volume":"19","author":"Gidding SS","year":"2024","unstructured":"Gidding SS, Ballantyne CM, Cuchel M, et al.. It is time to screen for homozygous familial hypercholesterolemia in the United States. Glob Heart. 2024, 19:43. 10.5334\/gh.1316","journal-title":"Glob Heart"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan MP","year":"2019","unstructured":"McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc. 2019, 8:e013225. 10.1161\/JAHA.119.013225","journal-title":"J Am Heart Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal FJ","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al.. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020, 382:1520-30. 10.1056\/NEJMoa1913805","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-015-0037-z","article-title":"Familial hypercholesterolemia: a review of the natural history, diagnosis, and management","volume":"4","author":"Najam O","year":"2015","unstructured":"Najam O, Ray KK. Familial hypercholesterolemia: a review of the natural history, diagnosis, and management. Cardiol Ther. 2015, 4:25-38. 10.1007\/s40119-015-0037-z","journal-title":"Cardiol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART Registry follow-up","volume":"67","author":"Perez de Isla L","year":"2016","unstructured":"Perez de Isla L, Alonso R, Watts GF, et al.. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART Registry follow-up. J Am Coll Cardiol. 2016, 67:1278-85. 10.1016\/j.jacc.2016.01.008","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-020-00884-2","article-title":"The knowns and unknowns of contemporary statin therapy for familial hypercholesterolemia","volume":"22","author":"Pang J","year":"2020","unstructured":"Pang J, Chan DC, Watts GF. The knowns and unknowns of contemporary statin therapy for familial hypercholesterolemia. Curr Atheroscler Rep. 2020, 22:64. 10.1007\/s11883-020-00884-2","journal-title":"Curr Atheroscler Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00926-3","article-title":"Current approach to the diagnosis and treatment of heterozygote and homozygous FH children and adolescents","volume":"23","author":"Cohen H","year":"2021","unstructured":"Cohen H, Stefanutti C. Current approach to the diagnosis and treatment of heterozygote and homozygous FH children and adolescents. Curr Atheroscler Rep. 2021, 23:30. 10.1007\/s11883-021-00926-3","journal-title":"Curr Atheroscler Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70174","article-title":"PCSK9 inhibitors: the evolving future","volume":"7","author":"Jeswani BM","year":"2024","unstructured":"Jeswani BM, Sharma S, Rathore SS, Nazir A, Bhatheja R, Kapoor K. PCSK9 inhibitors: the evolving future. Health Sci Rep. 2024, 7:e70174. 10.1002\/hsr2.70174","journal-title":"Health Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2020.1801452","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update","volume":"9","author":"Kaddoura R","year":"2020","unstructured":"Kaddoura R, Orabi B, Salam AM. Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update. J Drug Assess. 2020, 9:129-44. 10.1080\/21556660.2020.1801452","journal-title":"J Drug Assess"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S261719","article-title":"Cardiovascular outcomes and proprotein convertase subtilisin\/kexin type 9 inhibitors: current data and future prospects","volume":"16","author":"Duprez DA","year":"2020","unstructured":"Duprez DA, Handelsman Y, Koren M. Cardiovascular outcomes and proprotein convertase subtilisin\/kexin type 9 inhibitors: current data and future prospects. Vasc Health Risk Manag. 2020, 16:403-18. 10.2147\/VHRM.S261719","journal-title":"Vasc Health Risk Manag"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos RD","year":"2016","unstructured":"Santos RD, Gidding SS, Hegele RA, et al.. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016, 4:850-61. 10.1016\/S2213-8587(16)30041-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.12.009","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia","volume":"15","author":"Jackson CL","year":"2021","unstructured":"Jackson CL, Deng Y, Yao X, Van Houten H, Shah ND, Kopecky S. Proprotein convertase subtilisin\/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia. J Clin Lipidol. 2021, 15:339-46. 10.1016\/j.jacl.2020.12.009","journal-title":"J Clin Lipidol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011246","article-title":"PCSK9 inhibitor use in the real world: data from the national patient-centered research network","volume":"8","author":"Chamberlain AM","year":"2019","unstructured":"Chamberlain AM, Gong Y, Shaw KM, et al.. PCSK9 inhibitor use in the real world: data from the national patient-centered research network. J Am Heart Assoc. 2019, 8:e011246. 10.1161\/JAHA.118.011246","journal-title":"J Am Heart Assoc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3451","article-title":"Association of prior authorization and out-of-pocket costs with patient access to pcsk9 inhibitor therapy","volume":"2","author":"Navar AM","year":"2017","unstructured":"Navar AM, Taylor B, Mulder H, et al.. Association of prior authorization and out-of-pocket costs with patient access to pcsk9 inhibitor therapy. JAMA Cardiol. 2017, 2:1217-25. 10.1001\/jamacardio.2017.3451","journal-title":"JAMA Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005404","article-title":"Effect of access to prescribed PCSK9 Inhibitors on cardiovascular outcomes","volume":"12","author":"Myers KD","year":"2019","unstructured":"Myers KD, Farboodi N, Mwamburi M, et al.. Effect of access to prescribed PCSK9 Inhibitors on cardiovascular outcomes. Circ Cardiovasc Qual Outcomes. 2019, 12:e005404. 10.1161\/CIRCOUTCOMES.118.005404","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S143008","article-title":"Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice","volume":"13","author":"Fairman KA","year":"2017","unstructured":"Fairman KA, Davis LE, Sclar DA. Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice. Ther Clin Risk Manag. 2017, 13:957-65. 10.2147\/TCRM.S143008","journal-title":"Ther Clin Risk Manag"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjdsi.2024.100754","article-title":"The national ambulatory medical care survey (NAMCS) at fifty: Past and future","volume":"12","author":"Goodson JD","year":"2024","unstructured":"Goodson JD, Shahbazi S. The national ambulatory medical care survey (NAMCS) at fifty: Past and future. Healthc (Amst). 2024, 12:100754. 10.1016\/j.hjdsi.2024.100754","journal-title":"Healthc (Amst)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2020.0588","article-title":"Prescriptions for opioids and opioid-included polypharmacy: an analysis of the National Hospital Ambulatory Medical Care Survey","volume":"16","author":"Rivera JC","year":"2020","unstructured":"Rivera JC. Prescriptions for opioids and opioid-included polypharmacy: an analysis of the National Hospital Ambulatory Medical Care Survey. J Opioid Manag. 2020, 16:329-39. 10.5055\/jom.2020.0588","journal-title":"J Opioid Manag"},{"key":"ref21","unstructured":"National Hospital Ambulatory Medical Care Survey. (2024). Accessed. August 21, 2025: https:\/\/www.cdc.gov\/nchs\/nhamcs\/about\/index.html."},{"key":"ref22","unstructured":"Dataset documentation. (2024). Accessed. August 21, 2025: https:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Dataset_Documentation\/NAMCS\/stata\/."},{"key":"ref23","unstructured":"2025 ICD-10-cm diagnosis code E78.01. (2025). Accessed. August 21, 2025: https:\/\/www.icd10data.com\/ICD10CM\/Codes\/E00-E89\/E70-E88\/E78-\/E78.01."},{"key":"ref24","unstructured":"Multum consumer information. (2025). Accessed. August 21, 2025: https:\/\/www.drugs.com\/mtm\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/413440-prescribing-patterns-of-evolocumab-and-alirocumab-in-patients-with-familial-hypercholesterolemia-a-cross-sectional-study-using-the-national-ambulatory-medical-care-survey-2018-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:53:14Z","timestamp":1759398794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/413440-prescribing-patterns-of-evolocumab-and-alirocumab-in-patients-with-familial-hypercholesterolemia-a-cross-sectional-study-using-the-national-ambulatory-medical-care-survey-2018-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.93695","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}